LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System. The company offers LENSAR Laser System which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.

LENSAR, Inc.

Lake Street analyst Frank Takkinen reiterated a Buy rating on LENSAR today and set a price target of $13.00. According to TipRanks, Takkinen is a 3...

Lake Street Keeps Their Buy Rating on LENSAR (LNSR)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Candel Therapeutics (CADL), LENSAR (LNSR) and Pyxi...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	LNSR	$8.58	+4.00%	113.27K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	LNSR	$8.58	+4.0%	113.27K
3
4
5
6

LNSR

Get LENSAR, Inc. Data in Excel

Get LENSAR, Inc. Data in Excel